Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 3,714 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Muscle Disorders Clear all

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Not listed
Lead sponsor: Ipsen; Industry
Eligibility: 8 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 2
States / cities: San Francisco, California • Philadelphia, Pennsylvania

Conditions: Osteoarthritis, Tendinopathy, Impingement Shoulder
Interventions: Triamcinolone or Betamethasone, Dexamethasone; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Amyloidosis, Trigger Finger, Transthyretin Amyloidosis, Primary Amyloidosis of Light Chain Type
Interventions: Biopsy; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 50 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Critical Illness, Acute Kidney Injury, Sepsis, Septic Shock, Abdominal Compartment Syndrome
Interventions: Accuryn Monitoring System; Device
Lead sponsor: Potrero Medical; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Vasculitis
Interventions: Calm- Mindfulness Meditation smartphone application; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Trauma
Interventions: Mindfulness-Based Cognitive Therapy, Muscle Relaxation Therapy; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 72 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Columbus, Ohio

Conditions: Severe Spasticity
Interventions: Gablofen® 3 mg/mL (baclofen injection), SynchroMed® II Programmable Pump; Drug · Device
Lead sponsor: Piramal Critical Care, Ltd.; Industry
Eligibility: 4 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 13
States / cities: Little Rock, Arkansas • Loma Linda, California • Miami, Florida + 10 more

Conditions: Dermatomyositis, Polymyositis
Interventions: M5049 dose, Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 13
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 9 more

Conditions: Muscular Atrophy, Muscle Weakness
Interventions: Resistance Exercise, diet orange soda, essential amino acids; Behavioral · Dietary Supplement
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 50 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: ICU Acquired Weakness
Interventions: Electrical muscle stimulation; Device
Lead sponsor: Health Discovery Labs; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Exercise Induced Bronchospasm, Exercise Induced Asthma
Interventions: PrO2Fit Device; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Muscle Weakness, Dynapenia, Sarcopenia
Interventions: Action Observation; Other
Lead sponsor: University of Central Florida; Other
Eligibility: 60 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Whiplash Injury of Cervical Spine, Muscle Weakness
Interventions: Not listed
Lead sponsor: D'Youville College; Other
Eligibility: 19 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Tallahassee, Florida • Tampa, Florida

Conditions: Metabolic Syndrome
Interventions: Liraglutide, Exercise training, Liraglutide + Exercise training; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Larotrectinib Sulfate, Magnetic Resonance Imaging, Radionuclide Imaging, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 122
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more

Conditions: Obesity
Interventions: High-resistance inspiratory muscle strength training, Very-low-resistance inspiratory muscle strength training; Device
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Neuropathy, Muscle Disorders, Dysautonomia
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiomyopathy, Hypertrophic, Muscular Dystrophy, Oculopharyngeal
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Urinary Bladder Neoplasms
Interventions: AGEN1884, AGEN2034, Cisplatin, Gemcitabine; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Muscular Dystrophies, Muscle Myopathies, Hereditary Spastic Paraplegias, Inherited Neuropathies, Inherited Neuromuscular Conditions
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 1 Day to 100 Years
Enrollment: 2,586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cervicalgia, Low Back Pain
Interventions: Botulinum Toxins; Drug
Lead sponsor: VA Connecticut Healthcare System; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adrenocortical Carcinoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive, Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: cixutumumab, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 7 Months to 30 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 93
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more

Conditions: Spinal and Bulbar Muscular Atrophy
Interventions: BVS857, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Orange, California • Bethesda, Maryland • Columbus, Ohio

Conditions: Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 570 participants
Timeline: 2019 – 2029
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more

Search by objective public record fields.

A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Comparative Effectiveness of Particulate Versus Nonparticulate Steroid Injections for Musculoskeletal Conditions

Cardiac Amyloidosis Screening at Trigger Finger Release

Collective Accuryn Physiologic Signals and Signatures

Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases

Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for PTSD - COVID Related Substudy

Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump

Study of M5049 in DM and PM Participants (NEPTUNIA)

Combined Effects of Nutritional and Exercise Countermeasures

Safety and Efficacy of the MyokinE100 (CL-EMS Alpha) Device in Inducing Visible Muscle Contraction in Healthy Volunteers

Inspiratory Muscle Training on The Severity of Exercise-Induced Bronchoconstriction and Time-Trial Performance (IMT_EIB)

Mirror Neurons in Older Participants

Influence of Directional Preference on Movement Coordination Deficits in Individuals With Whiplash Associated Disorders

Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Inspiratory Muscle Strength Training in Adults With Obesity

Data Collection of Standard Care of Patients in the EMG Section

Study of Muscle Abnormalities in Patients With Specific Genetic Mutations

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Genetic and Physical Study of Childhood Nerve and Muscle Disorders

New Approaches in Evaluating Patients' Response to Botulinum Toxins in the Treatment of Chronic Neck Pain and Back Pain

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy

CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer